A phase II study of rituximab combined with pirarubicincyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma

Hisashi Tsurumi, Takeshi Hara, Naoe Goto, Jun Ichi Kitagawa, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Hideko Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Masahito Shimizu, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase II study of rituximab combined with pirarubicincyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences